Sponsors (2)
The bill improves access and national resilience for critical medicines through funded reserves and domestic manufacturing preferences, but does so at the cost of public spending, potential market concentration, higher operating/pricing pressures for some manufacturers and purchasers, and limits on private control of inventory during emergencies.
Patients who rely on critical drugs (including people with chronic conditions and seniors) are less likely to face shortages because awardees must hold multi‑month reserves and the Secretary can direct transfers during shortages.
Hospitals and health systems will have more reliable access to critical medicines during emergencies due to Secretary‑directed allocation and maintained reserves.
The bill strengthens U.S. drug‑supply resilience by favoring domestic and OECD‑based manufacturing and surge capacity, reducing dependence on single foreign sources.
Smaller generic manufacturers and some foreign suppliers that cannot meet domestic/OECD facility or surge‑capacity requirements may be excluded from awards, concentrating contracts among larger firms.
Requirements for recent production and regular replenishment of reserves could raise manufacturers' operating costs, which may be passed on as higher drug prices for patients and health systems.
Taxpayers may bear higher federal spending or budgetary tradeoffs because of the $500 million authorization and ongoing program costs.
Based on analysis of 2 sections of legislative text.
Requires HHS to contract with qualified manufacturers to maintain rolling multi-month reserves of critical drugs and APIs, publish a list, and allow Secretary-directed transfers during crises.
Introduced June 12, 2025 by Angela Craig · Last progress June 12, 2025
Creates a federal program for HHS to contract with qualified drug manufacturers to build and maintain rolling reserves of critical drugs and their active pharmaceutical ingredients (APIs) whose supply chains are vulnerable, and requires HHS to publish a list of those drugs/APIs. Participating manufacturers must hold a multi-month reserve (typically six months or another amount set by HHS) of both API and finished product at approved domestic or OECD-registered facilities, regularly replenish that stock with recently made supply, and be ready to produce additional quantities at the Secretary’s direction. Requires awardees to agree to transfer portions of API reserves to other manufacturers or allow Secretary-directed allocation when needed during public health emergencies, natural disasters, or chemical/biological/radiological/nuclear (CBRN) threats. HHS, working with the FDA Commissioner, must issue guidance within 180 days explaining how vulnerable supply chains will be identified, who is eligible, and what performance and capacity requirements awardees must meet.